The firm will use its solid-state nanopore technology to develop a point-of-care molecular diagnostic device to detect tuberculosis in low-resource areas.
Earlier this week, the company closed the sale of its US laboratory business to Quest DIagnostics for $170 million in cash.
The PCR assay is intended to help detect TB-causing bacteria and determine if it harbors mutations associated with isoniazid and rifampicin resistance.
Developers claim the immunochromatographic assay has advantages over other tests on the market for diagnosing TB in HIV patients, as well as the conventional approach.
The court ruled that Roche's claims are patent-ineligible because they are "directed to a natural phenomenon and lack any inventive concept" for a patent.
Already, public health organizations in the UK, the Netherlands, and New York state are moving toward implementing NGS for tuberculosis drug susceptibility testing.
The acquisition is expected to close in the fourth quarter and to increase US access to Oxford Immunotec Global's T-Spot.TB tuberculosis test.
The firm has been placing point-of-care systems primarily in the private sector, but may have increased access once it completes WHO prequalification review.
The workflow involves processing Qiagen's QuantiFeron-TB Gold Plus Blood Collection Tubes on DiaSorin's Liaison immunodiagnostic instruments.
NYSDOH's move away from susceptibility testing for isolates that are known to be pan-susceptible will be coordinated with similar international efforts.